However, few studies have reported the potential effects of bevacizumab in patients with EGFR-mutant NSCLC who develop BM, especially in those who received both EGFR-TKI treatment and cerebral radiotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.